Sunovion widens neurology pipeline through $624mm buy of Cynapsus
Sunovion Pharmaceuticals Inc. acquired public Canadian spec pharma Cynapsus Therapeutics Inc., paying $40.50 in cash per share (a 117% premium), valuing the transaction at $624mm. The deal has been approved by both company boards and is expected to close in Q4 2016.
- Specialty Pharmaceuticals
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.